Importance Hospitalized patients with COVID-19 pneumonia have high rates of morbidity
and mortality. Objective To assess the efficacy of colchicine in hospitalized patients with …

Abstract Purpose Coronavirus disease 2019 (COVID‐19) is associated with
hypercoagulability and increased thrombotic risk. The impact of prehospital antiplatelet …

Background Colchicine has been proposed as a potential therapy in coronavirus disease
2019 (COVID-19) due to their anti-inflammatory actions. Methods The COL-COVID study …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has become a global pandemic with a great impact on social …

Hospitalised patients with coronavirus disease 2019 (COVID-19) have a high mortality rate.
There are an increasing number of published randomised controlled trials for anti …

The management of patients presenting to healthcare services with SARS-CoV-2 infection
has developed rapidly over the past year, driven by the findings of high-quality randomised …

In contrast to reports made early in the pandemic, we show XLA patients remain susceptible
to severe disease. Persistent infection was common and is likely to carry a significant …

Abstract The SARS-CoV-2 B. 1.617. 2 (Delta) variant was first identified in the state of
Maharashtra in late 2020 and spread throughout India, displacing the B. 1.1. 7 (Alpha) …

Coronavirus disease 2019 (COVID-19) had caused huge health losses worldwide. Several
drugs had been applied to treat patients with COVID-19, and repurposing colchicine had …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the
COVID-19 pandemic. Currently, as dangerous mutations emerge, there is an increased …